Clinical Trial Update: Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC [Phase 3]

View source ↗

Summary

Phase 3 trial comparing tesetaxel plus reduced-dose capecitabine versus capecitabine in HER2-negative, HR-positive locally advanced/metastatic breast cancer was…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• tesetaxel (tesetaxel)

Snippet

Sponsor: Odonate Therapeutics, Inc. | Conditions: Breast Cancer | Phase 3 | Status: TERMINATED